Vineet Sankhla/X
Sep 8, 2026, 09:42
Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
Vineet Sankhla, Interventional Cardiologist Health New Zealand – Te Whatu Ora, shared a post on X:
“More bleeding with Prasu/Tica plus DOACs in AF patients undergoing PCI.
Clopidogrel may be safer choice in triple anti platelet therapy.
EPIDAURUS: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and ACS undergoing PCI.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral
-
Oct 21, 2026, 02:52Aymar Akilimali: Bleeding During Anticoagulation as a Potential Signal of Occult Cancer
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi
-
Oct 21, 2026, 00:56Caitlyn Mooney: Pulmonary Embolism in Athletes, Recognition and Return to Sport
-
Oct 21, 2026, 00:54Hani Karrar: Pleased to Share Our Review on Emicizumab in Hemophilia A Management
-
Oct 21, 2026, 00:53Akshay Sharma: HSCT Leads to Sustained Improvements in Sickle Cell Cardiomyopathy for Up to 3 Years
-
Oct 21, 2026, 00:51Prateek Meena: The F. A. T. R. N. Mnemonic for Recognizing TTP
-
Oct 20, 2026, 23:51Registration Is Open for WFH CCS 2027 – World Federation of Hemophilia
-
Oct 20, 2026, 23:44Edward Lee Carter: AF in Nursing Homes – When Stroke Risk Scores Tell Only Part of the Story